Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLunglife Ai Regulatory News (LLAI)

  • There is currently no data for LLAI

Holding(s) in Company

27 May 2025 07:00

RNS Number : 0676K
LungLife AI, INC
27 May 2025
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

USU5500L1045 and USU5500L1128

Issuer Name

LungLife AI, Inc.

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Cable Car Capital LLC

City of registered office (if applicable)

San Francisco

Country of registered office (if applicable)

United States

Name

City of registered office

Country of registered office

Funicular Funds, LP

San Francisco

United States

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

23-May-2025

6. Date on which Issuer notified

23-May-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

17.640000

0.000000

17.640000

5408142

Position of previous notification (if applicable)

16.450000

0.000000

16.450000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

USU5500L1045 and USU5500L1128

5408142

17.640000

Sub Total 8.A

5408142

17.640000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jacob Ma-Weaver

Cable Car Capital, LP

17.640000

0.000000

17.640000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Cable Car Capital, LP, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital, LP, may each be deemed the beneficial owner of the shares held by Funicular Funds, LP.

12. Date of Completion

23-May-2025

13. Place Of Completion

San Francisco, CA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFZGZKNFZGKZM
12
Date   Source Headline
29th May 20257:00 amRNSCancellation - LungLife AI, Inc.
27th May 20257:00 amRNSHolding(s) in Company
23rd May 20257:00 amRNSHolding(s) in Company
22nd May 20256:00 pmRNSLungLife AI
21st May 20257:01 amRNSHolding(s) in Company
21st May 20257:00 amRNSHolding(s) in Company
20th May 20255:15 pmRNSResult of Special Meeting
15th May 20257:00 amRNSHolding(s) in Company
15th May 20257:00 amRNSBlock listing Interim Review
14th May 20257:00 amRNSHolding(s) in Company
29th Apr 20257:00 amRNSNotice of Special Meeting
17th Apr 20257:00 amRNSLicense Agreement and Other Matters
10th Feb 20257:00 amRNSChange of Nominated Adviser and Joint Broker
3rd Feb 20257:00 amRNSOperational Update & Proposed Cancellation
19th Nov 20247:00 amRNSOperational update
15th Nov 20247:00 amRNSBlock listing Interim Review
25th Oct 20247:00 amRNSDirectorate Change
22nd Oct 20247:00 amRNSCancellation & Reissue Share Options, PDMR Notice
4th Oct 20247:00 amRNSOptions Cancellation and Re-issuance
2nd Oct 20247:00 amRNSLungLB® publication in peer-reviewed journal
2nd Sep 20247:00 amRNS-RData Supporting LungLB to be Presented at the AMP
22nd Aug 20247:00 amRNSHalf-year Report
16th Aug 20247:00 amRNSLCD coverage for Indeterminate Lung Nodules
15th Aug 20247:00 amRNSNotice of Results
5th Jun 20245:16 pmRNSResult of AGM
3rd Jun 202412:45 pmRNSConfirmation of AGM
15th May 20247:00 amRNSBlock Listing Six Monthly Return
2nd May 20244:04 pmRNSHolding(s) in Company
25th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
17th Apr 20247:00 amRNSPresentation at NCI's EDRN Meeting
4th Apr 20247:00 amRNSPreliminary Audited Results
27th Mar 20247:00 amRNSNotice of Results
26th Mar 20241:49 pmRNSHolding(s) in Company
25th Mar 202410:33 amRNSHolding(s) in Company
22nd Mar 20249:39 amRNSAdmission of New Shares & PDMR Dealing
22nd Mar 20248:21 amRNSAdmission of New Shares & PDMR Dealing
21st Mar 20242:05 pmRNSResult of Special Meeting
6th Mar 20245:35 pmRNSPosting of Circular and Notice of Special Meeting
5th Mar 20247:00 amRNSResults of Placing and Subscription
4th Mar 20244:56 pmRNSProposed equity raise of approximately £1.8m
2nd Jan 20247:00 amRNSSuccessful validation study results for LungLB®
15th Nov 20237:00 amRNSBlock Listing Six Monthly Return
28th Sep 20237:00 amRNSClinical validation study update
14th Aug 20231:32 pmRNSDirector share purchases
8th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
6th Jun 20237:00 amRNSLungLB® study published in peer-reviewed journal
23rd May 20237:00 amRNSEnrolment completed for LungLB® validation study
15th May 20237:00 amRNSBlock Listing Six Monthly Return
4th May 20235:49 pmRNSResult of AGM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.